Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - Elsevier
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - europepmc.org
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
[HTML][HTML] Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - ncbi.nlm.nih.gov
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
[引用][C] Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - cir.nii.ac.jp
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance
of the World Health Organization | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
of the World Health Organization | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - hub.hku.hk
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - pure.johnshopkins.edu
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - europepmc.org
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …